Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
EMUC 2026
Measuring the impact of fatigue on health-related quality of life in prostate cancer patients in the USA and Germany
- Fatigue has a measurable and consistent negative impact on patients with prostate cancer and their HRQoL Patients with symptoms other than fatigue, with ongoing hormone therapy, and metastatic disease were more likely to have fatigue
- To our knowledge, this is the first and largest cross-sectional study of patients with prostate cancer demonstrating that fatigue has a measurable and consistent negative impact on HRQoLacross three validated questionnaires
- Given the high burden and prevalence of fatigue among patients with prostate cancer, physicians should select treatment strategies associated with a lower burden of fatigue and educate patients on the importance of exercise to minimize the impact on patients’ overall HRQoL
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
